Quantum Genomics SA (ALQGC) - Total Liabilities
Based on the latest financial reports, Quantum Genomics SA (ALQGC) has total liabilities worth €2.81 Million EUR (≈ $3.29 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Quantum Genomics SA - Total Liabilities Trend (2009–2024)
This chart illustrates how Quantum Genomics SA's total liabilities have evolved over time, based on quarterly financial data. See ALQGC working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Quantum Genomics SA Competitors by Total Liabilities
The table below lists competitors of Quantum Genomics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Albion Resources Ltd
AU:ALB
|
Australia | AU$100.40K |
|
Indo Oil Perkasa PT
JK:OILS
|
Indonesia | Rp205.89 Billion |
|
Bumi Citra Permai Tbk
JK:BCIP
|
Indonesia | Rp399.66 Billion |
|
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
|
USA | $109.17 Million |
|
SIV Capital Ltd
AU:SIV
|
Australia | AU$113.58K |
|
Thunderstruck Resources Ltd
V:AWE
|
Canada | CA$747.18K |
|
Axiom Properties Ltd
AU:AXI
|
Australia | AU$6.62 Million |
|
Tartana Minerals Ltd
AU:TAT
|
Australia | AU$7.54 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Quantum Genomics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Quantum Genomics SA (ALQGC) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quantum Genomics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quantum Genomics SA (2009–2024)
The table below shows the annual total liabilities of Quantum Genomics SA from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.81 Million ≈ $3.29 Million |
-15.09% |
| 2023-12-31 | €3.31 Million ≈ $3.87 Million |
-83.49% |
| 2022-12-31 | €20.05 Million ≈ $23.44 Million |
+73.22% |
| 2021-12-31 | €11.57 Million ≈ $13.53 Million |
+42.06% |
| 2020-12-31 | €8.15 Million ≈ $9.53 Million |
+51.65% |
| 2019-12-31 | €5.37 Million ≈ $6.28 Million |
-18.75% |
| 2018-12-31 | €6.61 Million ≈ $7.73 Million |
+31.06% |
| 2017-12-31 | €5.05 Million ≈ $5.90 Million |
+85.70% |
| 2016-12-31 | €2.72 Million ≈ $3.18 Million |
+7.89% |
| 2015-12-31 | €2.52 Million ≈ $2.94 Million |
-48.42% |
| 2014-12-31 | €4.88 Million ≈ $5.71 Million |
+47.01% |
| 2013-12-31 | €3.32 Million ≈ $3.88 Million |
+68.19% |
| 2012-12-31 | €1.97 Million ≈ $2.31 Million |
+278.97% |
| 2011-12-31 | €521.06K ≈ $609.18K |
-35.26% |
| 2010-12-31 | €804.81K ≈ $940.91K |
+50.48% |
| 2009-12-31 | €534.82K ≈ $625.26K |
-- |
About Quantum Genomics SA
Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.